Trending
- Same mutagenic insult, different destinies: genetic background directs cancer evolution
- VIKTORIA-1 and Gedatolisib in HR+/HER2− mBC
- Managing Zongertinib Toxicities and Supporting Adherence
- Early Clinical Data Show KRAS Inhibitors Can Work in Cholangiocarcinoma
- Bridging therapy response and type as determinants of cilta-cel outcomes in relapsed/refractory multiple myeloma
- What Drove the SBRT Quality-of-Life Advantage in Pancreatic Cancer?
- Gedatolisib Toxicity and Treatment Education in HR+/HER2− mBC
- IMS 2026: Key Updates Across The Multiple Myeloma Paradigm
Friday, October 2